Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials
FUTURE ONCOLOGY (2018)
期刊
FUTURE ONCOLOGY
卷 14, 期 22, 页码 2293-2302出版社
FUTURE MEDICINE LTD
关键词
类别
资金
- NIH/NCI Cancer Center [P30 CA008748]
- BMS
作者
我是这篇论文的作者
推荐
Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma
Kai Hou, Xiaohui Xu, Xin Ge, Jiacen Jiang, Fan Ouyang
BIOFACTORS (2023)
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Qian Li, Jingjing Han, Yonglin Yang, Yu Chen
FRONTIERS IN IMMUNOLOGY (2022)
Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
Pei-Yi Chu, Shih-Hsuan Chan
CANCERS (2021)
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects
Raheleh Roudi, Alberto D'Angelo, Marianna Sirico, Navid Sobhani
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients
Ioannis A. Ziogas, Alexandros P. Evangeliou, Dimitrios Giannis, Muhammad H. Hayat, Konstantinos S. Mylonas, Samer Tohme, David A. Geller, Nahel Elias, Lipika Goyal, Georgios Tsoulfas
ONCOLOGIST (2021)
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Shuang Huang, Gang Zheng, Kai Yang
WORLD JOURNAL OF SURGICAL ONCOLOGY (2023)
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Nikolaos Machairas, Diamantis Tsilimigras, Timothy M. Pawlik
CANCERS (2022)
Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
David Reparaz, Belen Aparicio, Diana Llopiz, Sandra Hervas-Stubbs, Pablo Sarobe
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy
Elina Khatoon, Dey Parama, Aviral Kumar, Mohammed S. Alqahtani, Mohamed Abbas, Sosmitha Girisa, Gautam Sethi, Ajaikumar B. Kunnumakkara
LIFE SCIENCES (2022)
Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer
Hongsheng Zhang, Jintao Mi, Qi Xin, Weiwei Cao, Chunjiao Song, Naidan Zhang, Chengliang Yuan
FRONTIERS IN ONCOLOGY (2023)
The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
Zihan Zhao, Siyang Liu, Rui Sun, Wenjie Zhu, Yulin Zhang, Tianyao Liu, Tianhang Li, Ning Jiang, Hongqian Guo, Rong Yang
FRONTIERS IN IMMUNOLOGY (2023)
PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
Ilaria Porcellato, Samanta Mecocci, Chiara Brachelente, Katia Cappelli, Federico Armando, Alessia Tognoloni, Elisabetta Chiaradia, Valentina Stefanetti, Luca Mechelli, Marco Pepe, Rodolfo Gialletti, Benedetta Passeri, Alessandro Ghelardi, Elisabetta Razzuoli
ANIMALS (2021)
Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer
Daniel A. Fox, Deepak Bhamidipati, Tsuyoshi Konishi, Harmeet Kaur, Nancy You, Kanwal P. S. Raghav, Phillip S. Ge, Craig Messick, Benny Johnson, Van K. Morris, Jane V. Thomas, Preksha Shah, Brian K. Bednarski, Scott Kopetz, George J. Chang, Kaysia Ludford, Victoria Serpas Higbie, Michael J. Overman
EUROPEAN JOURNAL OF CANCER (2023)
Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy
Xianzhe Yu, Xiaoqian Zhai, Juan Wu, Qingbo Feng, Chenggong Hu, Lingling Zhu, Qinghua Zhou
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2024)
A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
James J. Harding, Ralf-Dieter Hofheinz, Elena Elez, Yasutoshi Kuboki, Drew W. Rasco, Michael Cecchini, Lin Shen, Elizabeth Dowling, Shorena Archuadze, Bruna Andrade de Pereira, Shubham Pant
JOURNAL OF CLINICAL ONCOLOGY (2022)
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau, Joong-Won Park, Richard S. Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Eric Assenat, Renata Zaucha, Junji Furuse, Ghassan K. Abou-Alfa, Anthony B. El-Khoueiry, Ignacio Melero, Damir Begic, Gong Chen, Jaclyn Neely, Tami Wisniewski, Marina Tschaika, Bruno Sangro
LANCET ONCOLOGY (2022)
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
James J. Harding, Ahmad Awada, Gael Roth, Thomas Decaens, Philippe Merle, Nuria Kotecki, Chantal Dreyer, Christelle Ansaldi, Madani Rachid, Soraya Mezouar, Agnes Menut, Eloine Nadeige Bestion, Valerie Paradis, Philippe Halfon, Ghassan K. Abou-Alfa, Eric Raymond
LIVER CANCER (2022)
Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment
Dazhi Liu, Michael A. Weintraub, Christine Garcia, Marcus D. Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J. Harding, Stephen Harnicar, Alexander Drilon, Komal Jhaveri, James H. Flory
CANCER MEDICINE (2022)
Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments
Darren Cowzer, James J. Harding
CANCERS (2022)
A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
J. J. Harding, R. D. Hofheinz, M. E. Elez Fernandez, Y. Kuboki, D. Rasco, M. Cecchini, L. Shen, S. Archuadze, J. Geng, F. Haderk, S. Pant
ANNALS OF ONCOLOGY (2022)
Rational development of combination therapies for biliary tract cancers
James J. Harding, Danny N. Khalil, Luca Fabris, Ghassan K. Abou-Alfa
JOURNAL OF HEPATOLOGY (2023)
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
James J. J. Harding, Christiane Jungels, Jean-Pascal Machiels, David C. C. Smith, Chris Walker, Tao Ji, Ping Jiang, Xin Li, Ekaterine Asatiani, Eric Van Cutsem, Ghassan K. K. Abou-Alfa
TARGETED ONCOLOGY (2023)
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
James J. Harding, Sarina A. Piha-Paul, Ronak H. H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Brana, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Monica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa
NATURE COMMUNICATIONS (2023)
Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival
Kevin C. Soares, Joshua S. Jolissaint, Sarah M. McIntyre, Kenneth P. Seier, Mithat Gonen, Carlie Sigel, Naaz Nasar, Andrea Cercek, James J. Harding, Nancy E. Kemeny, Louise C. Connell, Bas Groot Koerkamp, Vinod P. Balachandran, Michael I. D'Angelica, Jeffrey A. Drebin, T. Peter Kingham, Alice C. Wei, William R. Jarnagin
CANCER MEDICINE (2023)
Mitogen-Activated Pathway Kinase (MAPK) Inhibitor-Associated Retinopathy: Do features differ with upstream versus down-stream inhibition?
Jasmine H. Francis, William Foulsham, Julia Canestraro, James J. Harding, Eli L. Diamond, Alexander Drilon, David H. Abramson
OCULAR ONCOLOGY AND PATHOLOGY (2023)
Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation
Bruno Almeida Costa, Paulino Tallon de Lara, Wungki Park, Fergus Keane, James J. Harding, Danny N. Khalil
ONCOLOGY RESEARCH AND TREATMENT (2023)
Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver Chemistry
Enaksha Wickremsinhe, Antoniu Fantana, Erwin Berthier, Brook A. Quist, Diego Lopez de Castilla, Charles Fix, Kahlil Chan, Jing Shi, Michael G. Walker, Jennifer F. Kherani, Holly Knoderer, Arie Regev, James J. Harding
JOURNAL OF APPLIED LABORATORY MEDICINE (2023)
Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma
Tiago Biachi de Castria, Danny N. Khalil, James J. Harding, Eileen M. O'Reilly, Ghassan K. Abou-Alfa
FUTURE ONCOLOGY (2022)
Clinical and genomic characterization of ERBB2-altered gallbladder cancer.
Sebastian Mondaca, Nikolaus Schultz, Juan Carlos Roa, Henry S. Walch, Santiago Sepulveda, James J. Harding, Amin Yaqubie, Patricia Garcia, Gloria Aguayo, Bruno Nervi, Bob T. Li, Ghassan K. Abou-Alfa
JOURNAL OF CLINICAL ONCOLOGY (2022)